This suggests that further development of TWIST1 inhibitors is warranted as these would be expected to have broad activity against oncogenic driven NSCLC and specifically, both treatment naïve and MET TKI resistant MET driven tumors. The gene discussed is MET; the disease is non-small cell lung carcinoma.